Gut microbiota profiling in injection drug users with and without HIV-1 infection in Puerto RicoOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined the gut microbiome in people who inject drugs, comparing those with and without HIV-1 infection. Researchers used amplicon-based 16S rDNA sequencing to identify amplicon sequence variants (ASVs) and detect shifts in bacterial community composition. The goal was to disentangle how HIV status and injection drug use, separately and together, shape the gut microbiota. Effects of multiple drug use on the microbiome were also assessed in both HIV-infected and non-infected participants.
Who was studied?
The study drew on a well-established cohort of people who inject drugs in Puerto Rico, a region with historically high rates of injection drug use and an HIV incidence disproportionately linked to it. Participants included both HIV-positive and HIV-negative individuals, and both drug-injecting and non-injecting individuals, allowing comparison across these groups. The abstract does not give an exact sample size.
What were the most important findings?
HIV-positive individuals had a higher abundance of ASVs from the genera Prevotella, Alloprevotella, Sutterella, Megasphaera, Fusobacterium, and Mitsuokella. In contrast, Bifidobacteria and Lactobacillus ASVs were more abundant in people who inject drugs compared to non-injectors, regardless of HIV status. The study also found that using multiple drugs significantly affected the composition of the gut microbial community. These patterns show that HIV status and drug use each leave distinct, identifiable signatures on the gut microbiome.
What are the greatest implications of this study?
The findings suggest that HIV infection and injection drug use independently reshape the gut microbiome, producing distinguishable bacterial signatures rather than a single combined effect. Identifying HIV-associated genera separately from drug-use-associated genera could help researchers understand how each factor contributes to health outcomes in this population. Recognizing that multiple drug use further alters the microbial community underscores the need to account for drug use patterns in microbiome research on people with HIV. This work supports using gut microbiota profiling as a tool to better understand the intersecting effects of infection and substance use.